Related Experiment Videos
Utilizing angiogenic agents to expedite the neovascularization process in skin flaps
D B Hom1, S R Baker, L M Graham
1Department of Otolaryngology, University of Michigan Hospitals, Ann Arbor 48109.
The Laryngoscope
|May 1, 1988
Summary
Angiogenic agents like ECGS significantly improved skin flap survival by promoting new blood vessel growth. This research offers promising strategies for enhancing flap viability in reconstructive surgery.
Area of Science:
- Biomedical Engineering
- Wound Healing Research
- Tissue Engineering
Background:
- Skin flap survival is critical in reconstructive surgery.
- Neovascularization, or new blood vessel formation, is essential for flap survival.
- Current methods to enhance neovascularization are limited.
Purpose of the Study:
- To investigate the efficacy of angiogenic agents in accelerating skin flap neovascularization.
- To determine if angiogenic agents can increase the viability of transposed skin flaps.
- To evaluate the potential of Endothelial Cell Growth Supplement (ECGS) and Endothelial Cell Growth Factor (ECGF) in improving flap survival.
Main Methods:
- Eighty-four island skin flaps were created on New Zealand White rabbits.
- Flaps were treated with varying concentrations of ECGS or ECGF, topically or in Gelfoam.
- Control groups received normal saline treatment.
- Flap viability was assessed using polar planimetry, angiography, and histological analysis.
Main Results:
- ECGS-Gelfoam treated flaps showed 100% greater viability compared to saline-Gelfoam controls (p = .021).
- Angiography revealed enhanced vascular ingrowth in flaps treated with angiogenic agents.
- Histological analysis supported increased neovascularization in treated flaps.
Conclusions:
- Angiogenic agents, specifically ECGS, can significantly expedite neovascularization in skin flaps.
- These agents demonstrate potential to increase flap viability, reducing necrosis.
- The findings suggest a promising therapeutic approach for improving outcomes in skin flap surgery.